In an article published in The Lancet Oncology, Farge et al outlined the International Initiative on Thrombosis and Cancer (ITAC) 2022 clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism (VTE) in patients with cancer, including those infected with COVID-19.
The ITAC guidelines are available on a free, Web-based mobile phone application; more information is available at itaccme.com.
As stated by the authors, “Cancer-associated VTE, which includes deep-vein thrombosis, pulmonary embolism, and central venous catheter–related VTE, is the second-leading cause of death in patients with cancer after [disease] progression.”
Key recommendations from the 2022 guidelines, based on literature review through January 2022, include the following:
Guidance for Patients With Cancer Infected With COVID-19
Recommendations specifically for COVID-19–infected patients with cancer include:
The authors concluded, “Cancer-associated VTE remains an important clinical problem associated with increased morbidity and mortality. The 2022 updated ITAC guidelines incorporate emerging data within established approaches for the prevention and treatment of cancer-associated thrombosis. The ITAC guidelines’ companion free Web-based mobile application will assist the practicing clinician with decision-making at various levels to provide optimal care of patients with cancer to treat and prevent VTE.”
Dominique Farge, MD, PhD, of Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Nord-Université de Paris, is the corresponding author for The Lancet Oncology article.
Disclosure: For full disclosures of the study authors, visit thelancet.com.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.